246 related articles for article (PubMed ID: 21320304)
1. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.
Satheesha S; Cookson VJ; Coleman LJ; Ingram N; Madhok B; Hanby AM; Suleman CA; Sabine VS; Macaskill EJ; Bartlett JM; Dixon JM; McElwaine JN; Hughes TA
Mol Cancer; 2011 Feb; 10():19. PubMed ID: 21320304
[TBL] [Abstract][Full Text] [Related]
2. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation dynamics of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) is discordant with its potential to interact with eukaryotic initiation factor 4E (eIF4E).
Showkat M; Beigh MA; Bhat BB; Batool A; Andrabi KI
Cell Signal; 2014 Oct; 26(10):2117-21. PubMed ID: 24975846
[TBL] [Abstract][Full Text] [Related]
4. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ
J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449
[TBL] [Abstract][Full Text] [Related]
5. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
6. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.
Kuo SH; Hsu CH; Chen LT; Lu YS; Lin CH; Yeh PY; Jeng HJ; Gao M; Yeh KH; Cheng AL
Eur J Cancer; 2011 May; 47(8):1244-57. PubMed ID: 21334199
[TBL] [Abstract][Full Text] [Related]
7. RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation.
Villalonga P; Fernández de Mattos S; Ridley AJ
J Biol Chem; 2009 Dec; 284(51):35287-96. PubMed ID: 19850923
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.
Nishi T; Iwasaki K; Ohashi N; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kobayashi T; Kodera Y
Cancer Lett; 2013 May; 331(2):220-9. PubMed ID: 23340172
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity.
Coleman LJ; Peter MB; Teall TJ; Brannan RA; Hanby AM; Honarpisheh H; Shaaban AM; Smith L; Speirs V; Verghese ET; McElwaine JN; Hughes TA
Br J Cancer; 2009 May; 100(9):1393-9. PubMed ID: 19367274
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1.
Grosso S; Pesce E; Brina D; Beugnet A; Loreni F; Biffo S
PLoS One; 2011; 6(12):e29136. PubMed ID: 22216185
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
12. p-mTOR, p-4EBP-1 and eIF4E expression in canine prostatic carcinoma.
Rivera-Calderón LG; Fonseca-Alves CE; Kobayashi PE; Carvalho M; Vasconcelos RO; Laufer-Amorim R
Res Vet Sci; 2019 Feb; 122():86-92. PubMed ID: 30476726
[TBL] [Abstract][Full Text] [Related]
13. The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model.
Pons B; Peg V; Vázquez-Sánchez MA; López-Vicente L; Argelaguet E; Coch L; Martínez A; Hernández-Losa J; Armengol G; Ramon Y Cajal S
Int J Oncol; 2011 Nov; 39(5):1337-45. PubMed ID: 21750861
[TBL] [Abstract][Full Text] [Related]
14. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.
Soni A; Akcakanat A; Singh G; Luyimbazi D; Zheng Y; Kim D; Gonzalez-Angulo A; Meric-Bernstam F
Mol Cancer Ther; 2008 Jul; 7(7):1782-8. PubMed ID: 18644990
[TBL] [Abstract][Full Text] [Related]
15. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
[TBL] [Abstract][Full Text] [Related]
16. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Ducker GS; Atreya CE; Simko JP; Hom YK; Matli MR; Benes CH; Hann B; Nakakura EK; Bergsland EK; Donner DB; Settleman J; Shokat KM; Warren RS
Oncogene; 2014 Mar; 33(12):1590-600. PubMed ID: 23542178
[TBL] [Abstract][Full Text] [Related]
17. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
18. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
He K; Zheng X; Li M; Zhang L; Yu J
Oncogene; 2016 Jan; 35(2):148-57. PubMed ID: 25867072
[TBL] [Abstract][Full Text] [Related]
20. The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets.
Maracci C; Motta S; Romagnoli A; Costantino M; Perego P; Di Marino D
Curr Med Chem; 2022; 29(20):3501-3529. PubMed ID: 35209811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
